AHA Coding Clinic® for HCPCS - 2009 Quarter 2; FOR your INFORMATION
New HCPCS Code
Certolizumab pegol, trade name Cimzia, is a therapeutic monoclonal antibody utilized in the treatment of Crohn’s disease. It is administered via subcutaneous injections in the abdomen or thigh. This drug was approved by the Food and Drug Administration on April 22, 2008. A new HCPCS code was created by CMS for the certolizumab pegol injection. This code became effective April 1, 2009. HCPCS—Long Descriptor Code C9249 —Injection, certolizumab pegol, 1 mg As a reminder, report units of service based on the HCPCS code long descriptor and the dosage used for the patient. In addition always check...
Subscribe or sign in to view the full article.
Article Overview
This article is a short HCPCS update focused on a newly created code for a specific injectable biologic therapy, along with its effective date and general reminders about reporting units based on the HCPCS long descriptor. It is relevant to medical coders, billing staff, and compliance teams monitoring HCPCS changes from CMS and FDA-related drug updates.
Why This Topic Matters
Short code-update articles like this help coding and billing professionals track newly established HCPCS entries and stay aware of timing and reporting references tied to the code’s long descriptor.
What You Will Learn
- How the article frames a new HCPCS update
- Which general type of therapy the update concerns
- What effective date information is noted
- Why long descriptor review is mentioned in the context of reporting units
Who Should Read This
- Medical coders
- Billing specialists
- Compliance staff
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com